astrzalek

7 POSTS 0 COMMENTS

VIVO 12-month results show “very good early success, excellent safety and...

Anthony Comerota (Alexandria, USA), global principal investigator of the VIVO trial, discusses the highlights of the 12-month results of the VIVO clinical study that...

CLEAR-DVT highlights “real paradigm shift” in treatment of DVT patients

Venous News takes a look back at VIVA 2019 (Vascular InterVentional Advances; 4–7 November, Las Vegas, USA) where Stephen Black (London, UK) and Mitchell Silver (Columbus, USA) discuss the CLEAR-DVT study.  Silver touches...

VeClose five-year data give confidence about long-term durability of VenaSeal treatment

   Kathleen Gibson (Bellevue, USA) put the five-year data from the VeClose study, which looked at the treatment of patients with venous reflux in the...

Telehealth ‘will change the future of venous practice’ post COVID-19

Six venous specialists, Manj Gohel (Cambridge, UK), Ian Franklin (London, UK) Alun Davies (London, UK), Sriram Narayanan (Singapore), Raghu Kolluri (Columbus, USA)...

Thrombosis is major by-product of infection with COVID-19, but evidence to...

Manj Gohel (Cambridge, UK), one of the editors-in-chief of Venous News, introduces a special COVID-19 video with leading thrombosis and haemostasis experts, including Beverley...

First look at CLOUT registry reveals over 75% of DVT patients...

David J. Dexter, (Sentara Healthcare, Norfolk, VA, USA), principal investigator of the CLOUT registry using the ClotTriever Mechanical Thrombectomy System (Inari Medical) for treatment...

The new Venovo Venous Stent is changing clinical practice

Steven Dubenec (Sydney, Australia) and Gerard O’Sullivan (Galway, Ireland) discuss the impact of dedicated venous stents, in particular the Venovo venous stent (BD, formerly...